TD Cowen

Bevi is a manufacturer of bottle-less water dispensers designed for offices and commercial spaces. The company's innovative products enable users to create custom beverages while accessing nutritional information and tracking the environmental impact of their choices. By utilizing the municipal water supply, Bevi aims to eliminate waste associated with the production, shipping, and disposal of bottled beverages. The dispensers offer a range of flavors made from real fruit essence, promoting healthier and more sustainable hydration options for employees in various settings.

Full-Service Institutional-Grade Prime Brokerage for Digital Asset Management. DLCC offers full-service Prime Brokerage solutions for digital assets. Our all-in-one user interface leverages both API and Saas product offerings to connect clients with a growing network of liquidity providers to transact, borrow, and lend digital assets, and manage collateral. Our product suite also offers traditional Prime Brokerage services, such as consultation and capital introduction.

Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

AlphaSense, Inc. is a New York-based company that specializes in developing an AI-powered search engine for market intelligence. Founded in 2007, AlphaSense provides a platform that enables research professionals to efficiently search, navigate, and analyze various data sources, including filings, research, news, and other disclosures. This technology utilizes artificial intelligence and natural language processing to identify relevant insights from diverse and fragmented data sets, helping users gain critical business insights quickly. The company serves over 1,000 enterprise clients across multiple industries and geographies. With a workforce exceeding 240 employees, a significant portion of whom are dedicated to product development, AlphaSense also has offices in London, Helsinki, Pune, and other locations in the United States.

Quip NYC, Inc., doing business as quip, designs, manufactures, and sells oral healthcare products. It offers electric toothbrushes; toothpastes; refillable floss pick and string; toothpaste; and supplies, such as toothbrush heads, travel cover mounts, manual toothbrushes, and refresh bag and chargers. The company sells its products through its online platform. Quip NYC, Inc. was founded in 2014 and is based in Brooklyn, New York.

ecoATM, LLC specializes in the recycling of electronic devices, including cell phones, tablets, and MP3 players, through automated kiosks located throughout the United States. Founded in 2008 and based in San Diego, the company provides a convenient platform for consumers to sell unwanted electronics, offering cash on the spot for devices they no longer use. The kiosks, strategically placed in high-traffic areas such as malls and grocery stores, evaluate the worth of the devices and facilitate the transformation of used electronics into valuable materials like copper, silver, gold, and palladium. In 2015, ecoATM expanded its services by acquiring Gazelle, enhancing both online and kiosk experiences for consumers. Through its services, ecoATM promotes responsible consumption by providing an easy, safe, and fast way for individuals to trade in their devices while also offering certified pre-owned electronics at competitive prices.

PolySign, Inc. is a company based in Oakland, California, that specializes in providing custody services for digital assets, including cryptocurrencies. Founded in 2017, PolySign has developed a secure and scalable infrastructure designed for financial institutions, enabling them to effectively manage and trade digital assets. The platform supports a wide range of digital assets and offers institutional-grade custodial services, allowing asset managers and exchanges to operate in a secure and accessible environment. By integrating with existing financial organizations and adhering to rigorous regulatory standards, PolySign aims to facilitate the broader adoption and utilization of digital assets in global markets.

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.

Proterra Inc. designs and manufactures zero-emission electric buses, specializing in heavy-duty vehicles that enable fleet operators to reduce operating costs and eliminate fossil fuel dependency. The company’s product lineup includes 35-foot and 40-foot Catalyst transit vehicles, which are built to meet the diverse mileage needs of urban and regional routes on a single charge. Proterra also provides a range of services, including pre-delivery consultations, training programs, mid-life inspections, and battery management services. Their offerings extend to energy services such as fleet planning, charging infrastructure, and telematics. Founded in 2004 and headquartered in Burlingame, California, Proterra has additional offices in South Carolina and California, and its products are designed, engineered, and manufactured in the United States. By helping customers transition to battery-electric transit solutions, Proterra has contributed to significant reductions in greenhouse gas emissions and fuel consumption.

Kyber Data Science LLC is a subsidiary of Cowen Inc. focused on developing and selling unique and proprietary datasets across a variety of sectors to institutional investors and corporations.

ecoATM, LLC specializes in the recycling of electronic devices, including cell phones, tablets, and MP3 players, through automated kiosks located throughout the United States. Founded in 2008 and based in San Diego, the company provides a convenient platform for consumers to sell unwanted electronics, offering cash on the spot for devices they no longer use. The kiosks, strategically placed in high-traffic areas such as malls and grocery stores, evaluate the worth of the devices and facilitate the transformation of used electronics into valuable materials like copper, silver, gold, and palladium. In 2015, ecoATM expanded its services by acquiring Gazelle, enhancing both online and kiosk experiences for consumers. Through its services, ecoATM promotes responsible consumption by providing an easy, safe, and fast way for individuals to trade in their devices while also offering certified pre-owned electronics at competitive prices.

Quarton International AG, formed in December 2015 through the merger of Blue Corporate Finance and Quarton Partners, provides a range of financial advisory services, including mergers and acquisitions, special situations, restructuring, and financing advisory. The firm specializes in sell-side and buy-side advisory for entrepreneur-owned middle market businesses and private equity firms, as well as offering strategic advisory related to insolvency and succession planning. It also engages in special situations and restructuring through 363 sales, out-of-court restructurings, and various financing options. Quarton International's financing advisory services encompass equity and debt financing, focusing on capital market transactions and medium-sized loans. The firm operates across multiple sectors, such as automotive, consumer goods, technology, real estate, and healthcare. Based in Munich, Germany, Quarton International has expanded its presence with offices in the United States and Europe. Following its acquisition by Cowen International Limited, the firm rebranded as Quarton, a Cowen Company, in January 2019.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.

As a leading technology firm, they provide mission critical software products and technology-enabled services to more than 6,000 clients in 100 markets. Their large and diverse client base of asset managers and financial intermediaries includes investment advisors, hedge funds, mutual funds, plan sponsors, trust banks, family offices, separately managed accounts, broker-dealers, exchanges, alternative trading systems, and investment banks.

CEFC China Energy Company Limited is a private collective enterprise that primarily focuses on energy and financial services. Its core business includes investing in oil and gas development through various subsidiaries, as well as operating oil and gas terminals, which encompass oil refineries and gas stations. The company aims to enhance international economic cooperation in the energy sector and is in the process of establishing an international investment bank and investment group to support its strategic goals.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.

Aquinox Pharmaceuticals Inc., based in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on discovering and developing oral drug candidates for the treatment of inflammatory diseases and cancer. Founded in 2004, the company is engaged in the development and commercialization of small molecule therapeutics. Its notable offerings include AQX-MN100, a drug targeting both cancer and inflammatory conditions, alongside a program aimed at SH2-containing inositol 5'-phosphatase inhibition for blood cell recovery. As of July 2020, Aquinox Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc.

Unum Therapeutics is a biopharmaceutical company focused on developing immunotherapy products for cancer treatment, utilizing proprietary T-cell engineering technology. The company’s lead programs, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, are in Phase I clinical trials. These include ACTR707 and ACTR087, both being tested in combination with rituximab for relapsed or refractory CD20+ non-Hodgkin lymphoma, as well as ACTR087 combined with SEA-BCMA for relapsed multiple myeloma. Additionally, ACTR707 is being evaluated with trastuzumab for HER2+ solid tumors. Unum Therapeutics is also exploring BOXR1030, a pre-clinical candidate targeting glypican-3 to enhance T cell functionality in the solid tumor microenvironment. Founded in 2014 and headquartered in Cambridge, Massachusetts, Unum aims to activate the body’s immune system to effectively combat cancer through its innovative therapies.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases, particularly heritable cardiomyopathies and genetically-driven heart failure. Founded in 2012 and headquartered in Brisbane, California, the company focuses on addressing biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, a small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company's preclinical pipeline includes programs targeting hypercontractility and impaired relaxation in HCM, as well as treatments for diastolic dysfunction. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Echo Global Logistics is a prominent provider of technology-enabled transportation and supply chain management services, specializing in multimodal shipping options. The company offers asset-light third-party logistics solutions, including intermodal and international air and ocean freight forwarding. By leveraging proprietary web-based technology, dedicated service teams, and strong procurement capabilities, Echo Global Logistics helps clients achieve significant savings in transportation costs while ensuring high-quality service. This focus on efficiency and competitive pricing positions the company as a valuable partner for businesses seeking to optimize their logistics operations.

Seabridge Gold's resource base of gold, copper and silver is one of the world's largest. Our principal projects are located in Canada. Our objective is to grow resource and reserve ownership per share. Our risk-reducing strategy: acquire North American deposits; expand them through exploration; move them to reserves through engineering; and sell or joint venture them to established producers for mine construction and operation.

Aptose Biosciences Inc. is a clinical-stage biotechnology company based in Toronto, Canada, specializing in the discovery and development of personalized cancer therapies. The company focuses on addressing unmet medical needs in oncology, particularly through its clinical programs targeting blood cancers. One of its key products, APTO-253, is currently undergoing a Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Additionally, Aptose has partnered with CrystalGenomics, Inc. to develop CG026806, a small molecule in Phase 1a/b trials for similar blood cancers. Another collaboration with OHM Oncology involves the development and commercialization of APL-581 for hematologic malignancies. Founded in 1986 and formerly known as Lorus Therapeutics Inc., Aptose continues to build a portfolio of innovative cancer treatments, emphasizing safety and efficacy.

Sesen Bio, Inc. is a late-stage clinical company focused on developing targeted fusion protein therapeutics for cancer treatment. Its lead product, Vicinium, is a locally-administered therapy currently undergoing phase 3 trials for high-risk non-muscle invasive bladder cancer (NMIBC). Vicinium is designed as a fusion protein that combines an anti-epithelial cell adhesion molecule antibody fragment with a cytotoxic protein to target cancer cells effectively. Additionally, Sesen Bio is exploring the use of Vicinium in combination with Durvalumab and other checkpoint inhibitors for various cancer indications, including squamous cell carcinoma of the head and neck. The company is also collaborating with Leiden University Medical Center on the co-development of an imaging agent. Founded in 2008 and headquartered in Cambridge, Massachusetts, Sesen Bio was previously known as Eleven Biotherapeutics before rebranding in May 2018.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating cancers and rare diseases driven by genomic abnormalities. The company’s pipeline includes avapritinib, which targets systemic mastocytosis and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders. Additionally, fisogatinib is in Phase I trials for advanced hepatocellular carcinoma, while pralsetinib targets RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Other investigational compounds include BLU-782, aimed at treating fibrodysplasia ossificans progressive. Established in 2008 and based in Cambridge, Massachusetts, Blueprint Medicines utilizes its proprietary chemical library and Insights-to-Validation Platform to develop personalized therapies that address specific molecular drivers of cancer and the challenges posed by resistance mechanisms. The company has formed collaboration agreements with several pharmaceutical entities to enhance its research and development efforts.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases, particularly heritable cardiomyopathies and genetically-driven heart failure. Founded in 2012 and headquartered in Brisbane, California, the company focuses on addressing biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, a small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company's preclinical pipeline includes programs targeting hypercontractility and impaired relaxation in HCM, as well as treatments for diastolic dysfunction. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.

GlassesOff is a health care technology company based in Hod Hasharon, HaMerkaz, that specializes in developing consumer-oriented software applications aimed at enhancing near vision sharpness. Founded in 2007, the company has created a non-invasive solution for individuals suffering from presbyopia, enabling them to reduce their reliance on reading glasses. Utilizing its proprietary technology platform, GlassesOff offers a personalized program that monitors users' performance and progress in addressing symptoms such as blurred near vision, eye fatigue, headaches, and slow reading. The software employs exercises designed to improve the image processing function in the visual cortex of the brain, thereby enhancing users' reading capabilities without altering the optical characteristics of the eye.

Dahlman Rose & Company, LLC was a research-driven investment bank that specialized in transportation, infrastructure, and sectors related to the global supply chain. Founded in 2004 and headquartered in New York, with additional offices in Boston, Houston, and San Francisco, the firm offered a range of services including institutional sales and trading, equity and fixed income research, mergers and acquisitions advisory, and underwriting. The team at Dahlman Rose focused on various verticals within the natural resources supply chain, covering areas such as marine shipping, offshore services, exploration and production, oilfield services, as well as coal, metals, mining, rail, trucking, and air freight. The firm was acquired by Cowen Group, Inc. in March 2013.

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.

Aurora Flight Sciences designs and builds aerospace vehicles for commercial and military applications. Aurora is headquartered in Manassas, VA, and operates production facilities in Bridgeport, WV, and Columbus, MS as well as a Research and Development Center in Cambridge, MA.

Reef is a global surf lifestyle brand founded by brothers Fernando and Santiago Aguerre, who sought to create high-quality active lifestyle sandals. Established in Southern California in 1984, the brand quickly gained recognition for its iconic open-toe footwear produced in Sao Paulo, Brazil. Inspired by the vibrant beach culture of South America, Reef introduced the Miss Reef concept, which became a symbol of the surfing community. Today, Reef offers a wide range of casual lifestyle footwear and apparel for men, women, and children, focusing on comfort, style, and functionality for those who embrace travel and adventure. The brand utilizes eco-friendly materials and advanced technology to create versatile products tailored for surfers and wanderers. Additionally, Reef supports an ambassador program that promotes talented athletes and adventurers, further solidifying its connection to the global surf culture.

Nextest Systems Corporation was founded in 1997 and shipped its first product in 1998. Nextest is a low-cost leader in the design and manufacture of ATE for non-volatile memory, microcontrollers, ASIC and System-On-a-Chip (SOC) semiconductors. Nextest's products address the growing demand from manufacturers for testing equipment with increased throughput, reliability, functionality and capacity, while reducing the time to market and cost of test. The company employs approximately 150 employees with sales and support offices worldwide. To date, Nextest has shipped over 1000 systems globally!

D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

SiberCore Technologies Incorporated is a pure-play, Internet IC company developing high-value-added Application Specific Standard Products (ASSPs) for intelligent hardware-based switching and routing platforms, such as Gigabit / Terabit Routers and Layer 2 / 3 / 4 Ethernet Switches. The company's initial products are a family of high-speed high-capacity packet forwarding engines based on Content Addressable Memories (CAM technology) which overcome the performance bottleneck associated with the network's routing table look-up function. This emerging market has been created by the demands of the explosion in datacom traffic, coupled with the worldwide deployment of fiber optics and DWDM. These broadband deployments have shifted the bottleneck from the Access and Transport section of the network, to the Routers and Switches connecting to these pipes. The company's founding technical team gained industry-wide recognition for its world-class design expertise in this area at Nortel Networks. A veteran Executive team in all the functional divisions of the company supplements this preeminent technical team.

TelOptica was funded in 1999 by communications network experts in optical, next-generation network design engineering and in operations research and algorithm development. The TelOptica team today includes highly regarded technologists with experience from established telco giants such as MCI and Sprint, international original equipment manufacturers such as Alcatel / DSC, Nortel, and IBM, and management consulting firms including McKinsey and Associates and Carreker Corporation. TelOptica is a well-funded, fast growing, privately held, optical communications technology company. TelOptica incorporated in Texas , received initial funding and support from the Startech business incubator of Richardson, Texas, and closed on its second round of funding from Trellis Partners, Austin Ventures, Centerpoint Ventures, SSM Ventures of Austin, and SG Cowen in June 2001.

The company provides enterprise portal software for the deployment and management of Intranet and extranet portals. The company's Coreport enterprise portal software allows businesses to provide all their stakeholders with a single, secure point of unified and personalized access to content, applications, processes, and services from any wired or wireless device.

ThoughtWorks, Inc. specializes in software delivery, tools, and consulting services tailored for organizations with ambitious goals across commercial, social, and government sectors. Founded in 1993 and headquartered in Chicago, the company develops a range of solutions including Mingle, a project management tool that aids in implementing agile practices; Go, an open-source continuous delivery server; Snap, a cloud deployment solution; and Twist, a test automation tool. ThoughtWorks emphasizes the importance of continuous improvement and quality in software development, utilizing agile methodologies. The organization is committed to social impact, partnering with humanitarian-focused groups to leverage technology for positive change. With a global presence, ThoughtWorks fosters a culture that values diversity, honesty, and inclusivity, promoting collaboration and innovation to drive progress in the software industry.

With more than 15 million page-views and more than 700,000 unique users per month, IPO.COM is the leading Internet provider of content and services to investors interested in initial public offerings, private placements and emerging growth companies. The company provides comprehensive IPO content including offering summaries, up-to-date pricing and filings, searchable EDGAR documents, daily columns and free weekly e-mail newsletters through the company's interactive portal and more than 150 financial web sites. Privately held, IPO.COM has offices in New York, Pennsylvania and California.

Tripod provides the tools to allow users to develop fully functional websites online with professional-looking templates and plugins. Tripod offers value-added services to let users take advantage of Search Engine Optimization professionals, Theme development by professional web designers as well as plugin development and site migration service by seasoned engineers.